More Than Conjugation: ADC Manufacturing
ADC manufacturing is becoming more complex as payloads, conjugation, lyophilisation, containment, and scale-up reshape CMC strategy and commercial readiness.
Antibody-drug conjugates (ADC) manufacturing is a demanding CMC discipline. ADCs are complex compounds that combine a biologic, a linker, and a highly potent small-molecule payload, requiring the need for formulation, stability, lyophilisation, scale-up, containment, and control strategy be designed as one manufacturing system.
Why ADC Manufacturing Requires a Different Development Strategy
ADCs are often discussed through the lens of conjugation chemistry. However, that is only the starting point.
An ADC brings together three components with different behaviours: A monoclonal antibody, a linker, and a cytotoxic payload.
Conjugation can change the molecule’s surface charge, hydrophobicity, solubility, aggregation behaviour, and thermal stability. A formulation that works for the parent antibody may therefore fail once the payload is attached.
That means ADC drug product development cannot simply inherit the process used for the unconjugated antibody. Teams need to understand how the final conjugate behaves during formulation, freezing, thawing, mixing, filtration, filling, storage, and reconstitution.
There has also been a broader shift within the field. As conjugation strategies become more sophisticated and higher drug-to-antibody ratios become viable, the challenge has moved from simply producing a conjugate to consistently producing the right conjugate with the right quality profile.
The critical quality attributes are expanding
For conventional biologics, teams already monitor attributes such as purity, aggregation, charge variants, and potency.
But ADCs add product-specific questions that can directly affect safety, efficacy, and process consistency.
Key attributes include:
- drug-to-antibody ratio (DAR) and drug-load distribution
- free or residual payload and unconjugated antibody
- aggregation and other size variants
- charge and hydrophobicity-related changes
- potency and relevant degradation products
The drug-to-antibody ratio is particularly important because payload loading influences both product performance and manufacturability. Higher loading can increase hydrophobicity and aggregation risk, meaning a process that achieves a higher DAR is not automatically a better process.
This creates a more integrated CMC problem. Analytical development must keep pace with process development so that changes in formulation or manufacturing can be linked to changes in the final product.
Stability Is the ADC Manufacturing Problem
The most important ADC manufacturing consideration is that ADC stability must be treated as an integrated property of the whole molecule.
Conjugation can introduce chemical liabilities in the linker or payload while also changing the physical behaviour of the antibody.
External stresses then add another layer of risk. Heat, pH shifts, freeze-thaw cycles, mechanical stress, light, and oxidation can contribute to aggregation, degradation, or premature payload release.
That matters because degradation is not only a shelf-life issue, as it can affect critical quality attributes linked to potency, pharmacokinetics, and safety.
Manufacturing environments are therefore part of the product strategy. Process conditions, hold times, light exposure, container selection, and handling need to be assessed for their potential effect on the ADC rather than assumed to behave like a conventional monoclonal antibody.
Packaging is part of the control strategy
Primary packaging also deserves earlier attention. ADCs can be sensitive to light, surface interactions, and formulation conditions. There is the importance of photoprotection and appropriate primary packaging during development to consider.
The same principle applies to fill-finish. Mixing, filtration, filling, and other downstream operations can influence product quality.
For Technical Operations teams, the drug product process should therefore be developed as a connected chain rather than as isolated unit operations.
This is particularly important as ADC manufacturing moves towards even more complex molecules and higher payload loading. The process must protect the molecule not only during production, but throughout storage, transport, preparation, and administration.
How AI Is Reshaping Data Integrity in Pharma Manufacturing
Veragence CEO Nour AlSaleh discusses how AI is transforming data integrity in pharma manufacturing, regulatory compliance, the "human-in-the-loop" requirement, and patient safety in the era of AI-driven GxP systems.
Why Lyophilisation Is Central to ADC Production
Lyophilisation has become a major tool for managing ADC stability. Many marketed ADCs use a freeze-dried presentation, although liquid and frozen approaches are also being explored.
The reason is practical. Some ADC linkers are vulnerable to degradation in aqueous environments. Removing water can reduce hydrolysis and help protect the conjugate during storage.
But lyophilisation does not remove manufacturing risk. It changes it.
The formulation must support freezing, primary drying, secondary drying, storage, and reconstitution without compromising the ADC.
Thermal properties such as the glass transition temperature of the maximally freeze-concentrated solution and collapse temperature are important inputs for cycle design.
The payload can also change the behaviour of the formulation. Increased hydrophobicity may raise self-association or aggregation risk, while excipient choices must balance stability, manufacturability, and reconstitution performance.
That makes lyophilisation a process-development discipline, not simply a final packaging step.
Design of Experiments and modelling can help teams understand the relationship between formulation composition, shelf temperature, drying conditions, product temperature, and resulting quality attributes. This becomes particularly valuable when transferring a cycle from development equipment to commercial-scale lyophilisers.
Containment must be designed into the process
ADC manufacturing also introduces an occupational safety dimension that conventional monoclonal antibody manufacturing does not face to the same extent.
Highly potent cytotoxic payloads require appropriate containment and exposure controls. Therefore, protective systems and the use of surrogate materials are central during process development where practical.
For manufacturing leaders, this changes facility and technology decisions. Equipment selection, material handling, cleaning strategy, operator protection, waste management, and facility flows all need to reflect the potency of the payload.
A technically sound ADC process that cannot be operated safely at scale is not a commercially viable process.
Scale-Up Must Protect Product Knowledge
Scale-up is where ADC manufacturing strategy is tested.
The underlying drug product process may resemble conventional mAb manufacturing, but ADC-specific risks mean that process transfer cannot rely on standard assumptions.
Changes in equipment geometry, mixing, heat transfer, lyophiliser loading, filtration, or hold conditions can expose weaknesses that were not visible at laboratory scale.
This is why scale-up should be treated as a knowledge-transfer exercise.
Surrogate vials can support lyophilisation development and scale-up, while modelling can reduce the number of experimental runs required to establish a robust cycle.
Design space approaches and Quality-by-Design (QbD) can also help teams understand which process parameters are most likely to affect product quality.
The goal is to establish a process that remains predictable as batch size, equipment, site, and manufacturing stage change.
The control strategy also needs to evolve with the programme.
Early clinical manufacturing may focus on demonstrating a workable process and supplying material. Later development requires stronger process understanding, defined operating ranges, analytical comparability, and evidence that the process can support consistent commercial production.
That makes early process characterisation strategically important. If it is later in an ADC programme when a scale-dependent stability or manufacturability problem is discovered, the greater the potential impact on timelines, technology transfer, capital requirements, and supply planning.
Maximise Pharma Innovation With Quality-by-Design
Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.
ADC Manufacturing Scalability and Stability Success
ADC manufacturing should be managed as an integrated CMC system rather than a sequence of independent development activities.
Three priorities stand out:
- Connect formulation, process, analytical, and containment knowledge. ADC-specific CQAs cannot be separated from the process conditions that create and protect them.
- Develop for scale early. Lyophilisation, packaging, fill-finish, and potent-compound handling can all create late-stage risks if treated as downstream problems.
- Make the control strategy part of development. QbD, risk assessment, modelling, and process characterisation can turn complex ADC behaviour into a more predictable manufacturing system.
The competitive advantage is being able to manufacture ADCs consistently, safely, at the required scale, and with a control strategy that can withstand lifecycle change.
This also changes how developers should assess external manufacturing partners. Capacity remains important, but ADC programmes may require specialised expertise across potent-compound handling, formulation, lyophilisation, conjugation-related analytics, fill-finish, scale-up, and technology transfer.
The right partner therefore needs to demonstrate process knowledge as well as available capacity.
The regulatory environment adds another consideration. ADCs sit across biologic and small-molecule characteristics, and the U.S. Food and Drug Administration (FDA) has issued dedicated clinical pharmacology guidance addressing their distinct development considerations.
For Technical Operations, this reinforces the need for strong product and process knowledge that can support the broader development and regulatory strategy.
Increasing molecular complexity, higher doses, alternative routes such as subcutaneous administration, and potential movement towards liquid or frozen presentations are also expected for ADCs going forward. Each change could introduce new formulation and manufacturing requirements.
All of this reinforces that ADC manufacturing capability is central to the value proposition of the molecule itself.
Think Scalability, Stability, and Reliability
As pipelines become more diverse, ADC manufacturing will increasingly influence the speed, cost, scalability, and reliability of development.
Companies that connect molecular design with formulation, process knowledge, analytical control, containment, and commercial readiness will be better positioned to move complex ADCs from clinical promise to reliable supply.
ADC manufacturing needs capability that connects molecular complexity with reliable commercial supply.
As payloads, formulation, lyophilisation, containment, analytical control, and scale-up become increasingly interdependent, Technical Operations teams need intelligence that connects decisions across the CMC lifecycle.
Pharmatica brings together the science, manufacturing strategy, regulatory landscape, and industry intelligence needed to turn complex life sciences challenges into clearer decisions and stronger execution.
Pharmatica: Insight. Connection. Impact.
Frequently Asked Questions
What is ADC manufacturing?
ADC manufacturing is the development and production of antibody-drug conjugate drug products, including formulation, processing, filling, lyophilisation where required, packaging, quality control, and scale-up.
Why is ADC manufacturing more complex than monoclonal antibody manufacturing?
ADC manufacturing must manage the additional effects of the linker and highly potent payload. These can alter hydrophobicity, aggregation, stability, drug loading, and degradation behaviour compared with the parent antibody.
Why are ADCs often lyophilised?
Lyophilisation can improve stability for ADCs with linkers that are vulnerable to degradation in aqueous environments. It can reduce hydrolysis and support longer-term drug product stability, although it introduces additional process-development requirements.
What are the key quality attributes in ADC manufacturing?
Important ADC quality attributes include drug-to-antibody ratio, drug-load distribution, free payload, unconjugated antibody, aggregation, charge variants, degradation products, and potency.
How can pharma companies improve ADC manufacturing scalability?
Companies can improve scalability by building process understanding early, using Quality-by-Design and risk-based development, applying modelling and Design of Experiments, and integrating formulation, analytical, containment, lyophilisation, and process development.
About the author
Did you enjoy the content?
Why not support Nicole Dale by giving this content a like
Comments (0)